- Home
- NNVC vs ZLAB Comparison
NNVC vs ZLAB Comparison
Compare NNVC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNVC
- ZLAB
- Stock Information
- Founded
- NNVC 2005
- ZLAB 2013
- Country
- NNVC United States
- ZLAB China
- Employees
- NNVC N/A
- ZLAB N/A
- Industry
- NNVC Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NNVC Health Care
- ZLAB Health Care
- Exchange
- NNVC Nasdaq
- ZLAB Nasdaq
- Market Cap
- NNVC 22.5M
- ZLAB 3.4B
- IPO Year
- NNVC N/A
- ZLAB 2017
- Fundamental
- Price
- NNVC $1.43
- ZLAB $32.86
- Analyst Decision
- NNVC
- ZLAB Buy
- Analyst Count
- NNVC 0
- ZLAB 6
- Target Price
- NNVC N/A
- ZLAB $57.22
- AVG Volume (30 Days)
- NNVC 112.7K
- ZLAB 819.9K
- Earning Date
- NNVC 11-13-2025
- ZLAB 11-11-2025
- Dividend Yield
- NNVC N/A
- ZLAB N/A
- EPS Growth
- NNVC N/A
- ZLAB N/A
- EPS
- NNVC N/A
- ZLAB N/A
- Revenue
- NNVC N/A
- ZLAB $427,799,000.00
- Revenue This Year
- NNVC N/A
- ZLAB $42.62
- Revenue Next Year
- NNVC N/A
- ZLAB $55.12
- P/E Ratio
- NNVC N/A
- ZLAB N/A
- Revenue Growth
- NNVC N/A
- ZLAB 32.56
- 52 Week Low
- NNVC $0.94
- ZLAB $20.17
- 52 Week High
- NNVC $1.92
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- NNVC 45.86
- ZLAB 49.59
- Support Level
- NNVC $1.42
- ZLAB $31.68
- Resistance Level
- NNVC $1.47
- ZLAB $33.06
- Average True Range (ATR)
- NNVC 0.05
- ZLAB 1.33
- MACD
- NNVC 0.01
- ZLAB 0.27
- Stochastic Oscillator
- NNVC 52.67
- ZLAB 85.08
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.